Alex Herrera on Nivolumab/Brentuximab Vedotin Combination for Patients with Hodgkin Lymphoma

Video

Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.

Alex Herrera, MD, City of Hope Cancer Center, discusses patients’ reaction in the phase I/II trial of combination nivolumab/brentuximab vedotin in the second-line for patients with Hodgkin lymphoma.

Herrera emphasizes monitoring for infusion-related reactions when treating patients taking these two drugs together. There was an increased rate of these reactions in the study. However, the infusion-related reactions seen were mostly mild and were able to be treated with the standard supportive therapies. After treatment, the patients were able to resume infusion as normal.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Related Content
Graphic of a leukemia cell

FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel

Chris Ryan
June 28th 2025
Article

The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Illustration of two medical workers holding up a magnifying glass to a cross-section of a bone

Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment

Bridget Hoyt
June 21st 2025
Article

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Image of blood cells

Fast Track Status Given to Givinostat for Polycythemia Vera

Tim Cortese
May 11th 2025
Article

The safety and efficacy of givinostat is being assessed vs hydroxyurea in the phase 3 GIV-IN PV trial.

Line illustration of a clipboard that says "FDA" with an approval mark in front on a cornflower blue background

A Snapshot of April FDA Approvals in Oncology for Nurses and APPs

Bridget Hoyt
May 1st 2025
Article

Approvals in oncology during April included treatments for breast cancer, colorectal cancer, and more.